^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Ovarian Cancer
    Drug:EDIT-202 (NK cell stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASGCT 2022
    Title:

    EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing

    Published date:
    05/03/2022
    Excerpt:
    EDIT-202 induced significantly enhanced anti-tumor efficacy in vivo when evaluated using a SKOV3 HER2+ ovarian cancer model.